• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BNT162b2 mRNA加强针后血管免疫母细胞性T细胞淋巴瘤快速进展：一例报告

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report.

作者信息

Goldman Serge, Bron Dominique, Tousseyn Thomas, Vierasu Irina, Dewispelaere Laurent, Heimann Pierre, Cogan Elie, Goldman Michel

机构信息

Department of Nuclear Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Department of Hematology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

出版信息

Front Med (Lausanne). 2021 Nov 25;8:798095. doi: 10.3389/fmed.2021.798095. eCollection 2021.

DOI:10.3389/fmed.2021.798095
PMID:34901098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8656165/
Abstract

Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.

摘要

由于核苷修饰的mRNA疫苗会强烈激活滤泡辅助性T细胞，因此探究已获批的SARS-CoV-2 mRNA疫苗对影响该细胞类型的肿瘤可能产生的影响具有重要意义。在此，我们报告并讨论了一名近期诊断为血管免疫母细胞性T细胞淋巴瘤（AITL）的男性在接种BNT162b2 mRNA疫苗加强针后淋巴瘤病变意外快速进展的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7b/8656165/91da04c9f9ca/fmed-08-798095-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7b/8656165/e97958fd2c0b/fmed-08-798095-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7b/8656165/91da04c9f9ca/fmed-08-798095-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7b/8656165/e97958fd2c0b/fmed-08-798095-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7b/8656165/91da04c9f9ca/fmed-08-798095-g0002.jpg

相似文献

1
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report.BNT162b2 mRNA加强针后血管免疫母细胞性T细胞淋巴瘤快速进展：一例报告
Front Med (Lausanne). 2021 Nov 25;8:798095. doi: 10.3389/fmed.2021.798095. eCollection 2021.
2
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.异源 mRNA 疫苗作为加强针在老年人中高效召回 SARS-CoV-2 变体反应性 B 细胞和 T 应答。
J Med Virol. 2023 Jan;95(1):e28258. doi: 10.1002/jmv.28258. Epub 2022 Nov 16.
3
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
4
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.BNT162b2 BA.4/5 二价 mRNA 疫苗在美国大型医疗体系中针对一系列 COVID-19 结局的有效性：一项病例对照研究。
Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25.
5
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.在北欧国家奥密克戎为主导期间，不同异源第三剂疫苗接种方案对严重 COVID-19 的效果比较：基于人群的队列分析。
BMJ. 2023 Jul 24;382:e074325. doi: 10.1136/bmj-2022-074325.
6
Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.不同初级疫苗接种方案对基于 mRNA 的 SARS-CoV-2 加强疫苗有效性的比较：利用病毒观察社区队列中的试验模拟进行时变队列分析。
Int J Epidemiol. 2023 Apr 19;52(2):342-354. doi: 10.1093/ije/dyad002.
7
Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.奥密克戎 BA.1 特异性 T 细胞应答在香港接种科兴或辉瑞疫苗的成年人中的观察性队列研究。
Lancet Microbe. 2023 Jun;4(6):e418-e430. doi: 10.1016/S2666-5247(23)00006-X. Epub 2023 Apr 20.
8
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.针对 COVID-19 mRNA 疫苗 BNT162b2 作为灭活 SARS-CoV-2 病毒疫苗异源加强针的疫苗有效性的证据综合和汇总分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856. doi: 10.1080/21645515.2023.2165856. Epub 2023 Feb 1.
9
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.腺病毒载体疫苗（Ad26.COV2.S）初免后的加强免疫的免疫原性和反应原性。
N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19.
10
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors.接种疫苗后抗 SARS-CoV-2 抗体的衰减和 TNF 抑制剂治疗的银屑病关节炎患者接受 BNT162b2 mRNA 疫苗加强剂量的免疫原性。
Clin Exp Rheumatol. 2023 Jan;41(1):166-169. doi: 10.55563/clinexprheumatol/hptln9. Epub 2022 Nov 24.

引用本文的文献

1
COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province.2019冠状病毒病疫苗接种、全因死亡率和癌症住院情况：意大利某省的30个月队列研究
EXCLI J. 2025 Jul 1;24:690-707. doi: 10.17179/excli2025-8400. eCollection 2025.
2
A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.新型冠状病毒肺炎mRNA疫苗综合综述：制药新时代的未明确及未知方面、影响与挑战
Curr Top Med Chem. 2025;25(12):1467-1491. doi: 10.2174/0115680266325847241121034100.
3
The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement.

本文引用的文献

1
Evolving Bilateral Hypermetabolic Axillary Lymphadenopathy on FDG PET/CT Following 2-Dose COVID-19 Vaccination.两剂 COVID-19 疫苗接种后 FDG PET/CT 显示双侧高代谢腋窝淋巴结病。
Clin Nucl Med. 2021 Dec 1;46(12):1011-1012. doi: 10.1097/RLU.0000000000003711.
2
Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis.新冠疫苗接种后 2-[F]FDG PET/CT 检测到的代谢亢进淋巴结的患病率及意义：一项系统评价和荟萃分析
Pharmaceuticals (Basel). 2021 Aug 3;14(8):762. doi: 10.3390/ph14080762.
3
Features of Systemic Immune Response From COVID-19 Vaccination on 18F-FDG PET/CT.
世界卫生组织基于基因的抗COVID-19疫苗接种后不良反应因果关系评估算法：陷阱与改进建议
J Clin Med. 2024 Nov 30;13(23):7291. doi: 10.3390/jcm13237291.
4
Nodal T-Follicular Helper Cell Lymphoma, Angioimmunoblastic-Type, Diagnosed in a Patient with Psoriasis Following COVID-19 Vaccination under Adalimumab Treatment: A Causal Association?在接受阿达木单抗治疗的银屑病患者中，接种新冠疫苗后诊断出血管免疫母细胞型结节性T滤泡辅助细胞淋巴瘤：存在因果关联吗？
Indian J Dermatol. 2024 May-Jun;69(3):264-267. doi: 10.4103/ijd.ijd_93_23. Epub 2024 Jun 26.
5
Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report.接受第一剂辉瑞/生物科技（BNT162b2）疫苗后诊断为血管免疫母细胞性 T 细胞淋巴瘤：病例报告。
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241231645. doi: 10.1177/23247096241231645.
6
Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan.日本新冠疫情期间第三剂信使核糖核酸-脂质纳米颗粒疫苗接种后年龄调整癌症死亡率上升。
Cureus. 2024 Apr 8;16(4):e57860. doi: 10.7759/cureus.57860. eCollection 2024 Apr.
7
Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review.罕见的新冠疫苗副作用在混乱中被忽视了。新冠疫苗接种后的原发性皮肤淋巴瘤：一项系统综述。
Front Med (Lausanne). 2024 Apr 10;11:1325478. doi: 10.3389/fmed.2024.1325478. eCollection 2024.
8
Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors.病例报告：一例转移性BRAFV600突变黑色素瘤合并心力衰竭患者接受免疫检查点抑制剂和BRAF/MEK抑制剂治疗。
Front Oncol. 2024 Mar 11;14:1366532. doi: 10.3389/fonc.2024.1366532. eCollection 2024.
9
The mRNA-LNP vaccines - the good, the bad and the ugly?mRNA-LNP 疫苗——好、坏、丑？
Front Immunol. 2024 Feb 8;15:1336906. doi: 10.3389/fimmu.2024.1336906. eCollection 2024.
10
COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.新冠病毒mRNA疫苗：注册试验和全球疫苗接种运动的经验教训
Cureus. 2024 Jan 24;16(1):e52876. doi: 10.7759/cureus.52876. eCollection 2024 Jan.
COVID-19 疫苗接种后 18F-FDG PET/CT 的全身免疫反应特征。
Clin Nucl Med. 2022 Jan 1;47(1):e89-e90. doi: 10.1097/RLU.0000000000003859.
4
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.SARS-CoV-2 mRNA 疫苗可诱导持久的人体生发中心反应。
Nature. 2021 Aug;596(7870):109-113. doi: 10.1038/s41586-021-03738-2. Epub 2021 Jun 28.
5
COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine.基于 FDG PET/CT 的 COVID-19 疫苗接种相关性淋巴结病：腺病毒载体疫苗的特征性表现。
Clin Nucl Med. 2021 Oct 1;46(10):814-819. doi: 10.1097/RLU.0000000000003800.
6
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.巴伦替尼（Bamlanivimab）对比安慰剂对熟练护理和辅助生活设施居民和工作人员 COVID-19 发病率的影响：一项随机临床试验。
JAMA. 2021 Jul 6;326(1):46-55. doi: 10.1001/jama.2021.8828.
7
PET findings after COVID-19 vaccination: "Keep Calm and Carry On".新冠疫苗接种后的PET检查结果：“保持冷静，继续前行” 。
Clin Transl Imaging. 2021;9(3):209-214. doi: 10.1007/s40336-021-00430-3. Epub 2021 May 13.
8
Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review.接种 COVID-19 疫苗后的淋巴结病：影像学表现综述。
Acad Radiol. 2021 Aug;28(8):1058-1071. doi: 10.1016/j.acra.2021.04.007. Epub 2021 May 1.
9
Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [F]FDG PET-CT and relevance to study interpretation.BNT162b2 mRNA新冠疫苗接种后出现的高代谢性淋巴结病：通过[F]FDG PET-CT评估发病率及其与研究解读的相关性
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1854-1863. doi: 10.1007/s00259-021-05314-2. Epub 2021 Mar 27.
10
Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic Patients.COVID-19 疫苗接种者的淋巴结病：肿瘤患者的诊断难题。
Radiology. 2021 Jul;300(1):E296-E300. doi: 10.1148/radiol.2021210275. Epub 2021 Feb 24.